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Abstract  
 
Purpose: Transcription factor C/EBP-α (CCAAT/enhancer-binding protein alpha) acts as a master 
regulator of hepatic and myeloid functions and multiple oncogenic processes. MTL-CEBPA is a first-
in-class small activating RNA oligonucleotide drug which up-regulates C/EBP-α. 
Experimental Design: We conducted a phase I, open label, dose escalation trial of MTL-CEBPA in 
adults with advanced HCC with cirrhosis, or resulting from non-alcoholic steatohepatitis (NASH) or 
with liver metastases. Patients received intravenous MTL-CEBPA once a week for 3 weeks followed 
by a rest period of 1 week per treatment cycle in the dose escalation phase (3+3 design).  
Results: 38 participants have been treated across 6 dose levels (28-160 mg/m2) and 3 dosing 
schedules. 34 patients were evaluable for safety endpoints at 28 days. MTL-CEBPA treatment-
related adverse events were not associated with dose and no maximum dose was reached across 
the 3 schedules evaluated. Grade 3 treatment related adverse events occurred in 9 (24%) patients. 
In 24 HCC patients evaluable for efficacy, an objective tumour response was achieved in 1 patient 
[4%; partial response (PR) for over 2 years] and stable disease (SD) in 12 (50%). After discontinuation 
of MTL-CEBPA, seven patients were treated with tyrosine kinase inhibitors (TKI); 3 patients had a 
complete response with one further PR and two with SD. 
Conclusions: MTL-CEBPA is the first saRNA in clinical trials and demonstrates an acceptable safety 
profile and potential synergistic efficacy with TKIs in HCC. These encouraging Phase I data validate 
targeting of C/EBP-α and have prompted MTL-CEBPA + sorafenib combination studies in HCC. 
 




















Statement of translational relevance 
Preclinical data have emerged suggesting C/EBP-a effects on the tumour microenvironment through 
myeloid derived suppressor cells could enhance response to sorafenib. The data from this trial provide 
preliminary validation for targeting C/EBP-a in patients with advanced HCC, particularly in context of 






Primary liver cancer is the seventh most common cancer in terms of incidence and fourth in terms of 
cancer related mortality, globally accounting for more than 850,000 new cases annually and 9.1% of 
all cancer deaths1. The majority (70-90%) of patients with hepatocellular carcinoma (HCC) have a 
background of liver cirrhosis. Unfortunately most patients are diagnosed with advanced disease as 
less than 20% of all cirrhotic patients undergo screening2.  
Sorafenib, a multikinase inhibitor has been the first-line systemic treatment for HCC. However, the 
overall survival benefit with sorafenib in previously untreated patients with preserved liver function, 
good performance status and advanced disease although statistically significant, is disappointing (10.7 
vs 7.9 months)3. In addition, lenvatinib was approved by the FDA as first-line treatment based on the 
REFLECT trial which showed non-inferiority to sorafenib4. Regorafenib, ramicirumab and cabozantanib 
have demonstrated a further modest survival benefit in the second line setting5 . The programmed 
cell death protein-1 (PD-1) immune checkpoint inhibitors nivolumab and pembrolizumab although 
granted accelerated approval by the FDA in the second line setting, have recently failed to show 
superiority over sorafenib and best supportive care in phase III clinical trials6. Recently the IMBrave150 
study demonstrated that combination treatment with atezolizumab in combination with bevacizumab 
were associated with improved overall and progression-free survival compared with sorafenib in 
patients with unresectable HCC who have not received prior systemic therapy. Despite this, there is a 
significant unmet need for novel therapeutics for HCC.   
The transcription factor C/EBPα (CCAAT/enhancer-binding protein alpha) is a leucine zipper protein 
which acts as a master regulator of liver homeostasis, multiple oncogenic processes (including cell 
cycle control, proliferation and angiogenesis) and the haematopoietic myeloid cell lineage, in which it 
primes and activates the myeloid gene expression program by binding to promoters or enhancers of 
myeloid-related genes7,8. Deregulation of C/EBPα has been reported in several solid tumours including 
liver, breast and lung9. Additionally C/EBPα is down-regulated in myeloid-derived suppressor cells 
from tumour bearing mice and C/EBPα knock out mice display greater myeloid-derived suppressor 
cell tumour infiltration, vascularization and growth10. Up-regulation of C/EBPα in rodent models of 
liver cancer inhibited tumour growth11-13. The main mechanism of action of MTL-CEBPA is therefore 
on myeloid cell differentiation and their effect on the tumour microenvironment.   
MTL-CEBPA is a first in class small activating RNA therapeutic comprising SMARTICLES® liposomal 
nanoparticle encapsulating CEBPA-51, a 21-mer small activating 2’O-Me RNA oligonucleotide duplex 
designed to specifically target and up-regulate transcription of the CEBPA gene14. Transfection of 
CEBPA-51 in hepatic cell lines, increased levels of C/EBP-a and inhibited cell proliferation14,15. 
Administration of MTL-CEBPA in rodent models of liver cancer increased levels of C/EBP-a and 
inhibited tumour growth. 
In this first-in-human, first-in-class phase I dose and dose-frequency escalation study we evaluate the 
safety, pharmacokinetics, pharmacodynamics and clinical outcome of MTL-CEBPA in patients with 
advanced liver cancer. 
  
Materials and Methods 
 
Study design and participants  
We report an international multi-centre, non-comparative, open-label, phase I study in patients with 
advanced HCC to evaluate the safety of dose escalation and dose frequency escalation. The original 
trial protocol included patients with any liver cancer, however following recruitment of the first 6 
patients (4 colorectal liver metastases, 1 ampullary carcinoma metastasis & 1 HCC with cirrhosis) the 
protocol was amended to recruit only patients with HCC, with this being the intended target 
population of the subsequent dose expansion phase. This study was conducted at 10 tertiary centres 
and university hospitals in 3 countries (Singapore, Taiwan and United Kingdom).  
Eligible patients were at least 16 years old with histologically confirmed advanced HCC with cirrhosis, 
or resulting from NASH, with or without cirrhosis, and unsuitable for liver tumour surgery and/or 
refractory to radiotherapy and other therapies. Patients were required to have a Child-Pugh score of 
B8 or less and ECOG performance status of 0-1. Full inclusion and exclusion criteria are described in 
appendix A. All patients provided written informed consent, and the study protocol and amendments 
were approved by the relevant regulatory authority and each site’s institutional review board or 




MTL-CEBPA was administered by intravenous infusion over 60 minutes once a week for 3 weeks 
followed by a rest period of 1 week; this defines a 4-week cycle. MTL-CEBPA dosing was preceded by 
prednisolone/hydrocortisone and anti-histamine administration to minimise the risk of infusion 
reactions. The determination of the starting dose of MTL-CEBPA was based on GLP toxicology studies 
in Sprague Dawley rats and cynomolgus monkeys. Based on these data, a starting dose of MTL-CEBPA 
28 mg/m2 was considered safe in humans. 
 
The dose escalation phase of the study followed a standard 3+3 design (Supplementary Figure 1) with 
the intention of determining the maximum tolerated dose. Six cohorts (cohorts 1 – 6) of 3 eligible 
participants were planned at the following doses: 28, 47, 70, 98, 130, 160 mg/m2 weekly (QW). The 
dose was based on body surface area (BSA) calculation on day 1 of each cycle. After a protocol 
amendment, three further cohorts (7-9) were evaluated for dose frequency escalation at 70 mg/m2 
(BIW d1,2, BIW d1,3 & TIW d1,2,3). Steroid and antihistamine re-dosing was only administered before 
the first dose of each week.  
 
The dose-limiting toxicities (DLT) were determined on the basis of the incidence and severity of AEs 
occurring in the first cycle (28 days). Patients were treated until disease progression or unacceptable 
toxicity. A Safety Review Committee (SRC) was convened to oversee safety, scientific integrity and 
validity of the study. Safety and tolerability of MTL-CEBPA was evaluated in terms of frequency of AEs 
graded according to toxicity criteria (NCI Common Terminology Criteria for Adverse Events, CTCAE v 
4.03). Patients off treatment were followed up for survival every 3 months. Tumour response and 




The primary endpoint was DLT defined as any drug related toxicity grade ≥3 according to the (CTCAE 
v4.03) with the only exception of aspartate transaminase (AST)/ alanine transaminase (ALT) related 
DLT defined as Grade 4 AST and/ or ALT abnormal laboratory value >20.0 x upper limit of normal 
(ULN).  
Secondary endpoints included incidence of toxicity as measured by AEs & serious adverse events 
(SAEs), determination of pharmacokinetic & pharmacodynamic parameters, tumour response and 
progression-free survival.  
 
Pharmacokinetics 
Because of the stability of SMARTICLES® liposomal nanoparticles in plasma and the rapid degradation 
and elimination of free CEBPA-51 (the active pharmaceutical ingredient) in plasma, it is expected that 
the plasma concentration measurements of CEBPA-51 reflect the concentration of CEBPA-51 
encapsulated in intact MTL-CEBPA nanoparticles. A fluorescently labelled peptide nucleic acid (PNA)-
probe, designed against the guide strand of CEBPA-51, was used to extract the single-stranded parent 
compound. RNA species are quantitated using anion-exchange HPLC and fluorescence detection. 
Plasma CEBPA-51 is expressed as µg/mL of double-stranded RNA and the lower limit of quantitation 
is 0.001 µg/mL.  
Plasma samples for analysis of CEBPA were collected over the first dosing interval for each Q1wk 
regimen and for 72h after administration of the second dose. After more frequent dosing with 70 
mg/m2 MTL-CEBPA, either twice-weekly (D1, D2 or D1, D3) or three-times weekly (D1, D2, D3) plasma 
CEBPA concentrations were measured over the first dosing interval (i.e. between the first and the 
second dose), at trough (prior to the next dose), 24h after the last dose and at 168h after the first dose 
(i.e. prior to the next cycle). 
 
Pharmacodynamics 
10ml of blood was collected in EDTA vacutainers (BD) and captured in a LeukoLOCKTM filter system 
(Ambion) modified for use for the OUTREACH study. Briefly, the filter captured WBC from whole blood 
whilst all remaining blood component were flushed out. The filter content was then preserved with 
RNALater solution and stored at -80oC for total RNA extraction. Total RNA was then isolated from the 
captured WBC by using a modified trizol extraction method. The captured RNA was then analysed for 
concentration (Nanodrop) and RNA integrity (Qbit) before proceeding to cDNA synthesis using 
Quantitect reverse transcription (Qiagen), kit. Transcript levels were measured by qPCR (QuantStudio 
5). qPCR was used to record WBC mRNA levels of CEBPA, adenosine, CXCR4, CD274 (PD-1) for select 
samples of individual patients. Samples were collected at pre-treatment (before start of infusion/Day 
1) and then 24hr post treatment (Day 2) as well as 7 days later (Day 8) and 7 days after second cycle 
(Day 15). All enrolled patients were considered for pharmacodynamic evaluation.  
Complement factor such as C3b and Bb as well as a cytokine panel (IL-2, IL-4, IL-6, IL-10, IL-17a, TNF-a 
and IFN-g) were studied in plasma as part of the safety monitoring of the patients using evidence 
Investigator Biochip Array technology and ELISA assays.  
 
Statistical analysis  
Descriptive statistics were used to characterise safety analyses. Kaplan-Meier methodology was used 
to determine means and 95% CIs for progression-free survival.  Sample sizes for each dose were 
determined on the basis of observed toxicities, not statistical considerations. Plasma CEBPA 
concentrations over the first dosing interval, after once-weekly dosing with MTL-CEBPA, were used to 







Between May 2016 and September 2018, 38 patients were enrolled in the trial, of which 34 were 
evaluable for safety endpoints at 28 days. Twenty four patients were enrolled in the dose escalation 
phase at once weekly doses of 28mg/m2 (n=5), 47 mg/m2 (n=4), 70 mg/m2 (n=6), 98 mg/m2 (n=3), 
130 mg/m2 (n=3) & 160 mg/m2 (n=3) and 14 patients in the dose frequency escalation at 70mg/m2 
on weekly days 1 & 2 (n=6), days 1 & 3 (n=5), and days 1, 2 & 3 (n=3) per week. 
Patient demographics and baseline characteristics including previous treatments are presented in 
Table 1. Overall, 35 patients have discontinued treatment as of the cut-off date. (29 disease 
progression, 4 study drug toxicity, 1 unrelated adverse event, 1 patient decision) 
 
The majority of patients were of Caucasian ethnicity (n=20) followed by Chinese (n=13), Asian (n=2) 
and Other (n=3). The median number of lines of systemic treatment that patients received before 
study enrolment was 1 (range 1-5). Of the overall patient cohort the mean index platelet count was 




Please insert Tables 1 & 2 here 
 
Dose escalation and safety   
34 patients were evaluable for safety endpoints at 28 days. A maximum tolerated dose was not 
reached. Grade 3 treatment-related AEs occurred in 9 (24%) patients. Treatment-related AEs (all 
grades) that occurred in more than 10% of patients were fatigue (23.7%), thrombocytopaenia (13.2%), 
anaemia(13.2%), elevated AST(13.2%), elevated ALP(10.5%), hypoalbuminaemia(10.5%), increased 
ALT(10.5%) and increased bilirubin(10.5%). The changes in liver function tests were generally 
transient such that overall there were no significant changes in LFTs at the end of the first and second 
cycles of treatment compared to baseline. Treatment-related SAEs were reported in 4 (11%) patients. 
Two of these patients are described below under treatment withdrawal (acute coronary syndrome & 
hyperbilirubinaemia). Of the two patients who were not withdrawn, one experienced haemorrhage 
from a stoma and the other an upper respiratory tract infection. Three (7.9%) patients died whilst on 
study (2 from disease progression and one related to upper GI bleeding from a duodenal ulcer on 
background of NSAID therapy), and there are no treatment-related deaths.  
Two patients were withdrawn with suspected drug-related toxicity which were subsequently deemed 
by the SRC to be not likely drug-related and therefore the relevant cohorts were not expanded (acute 
coronary syndrome on background of pre-morbid atherosclerotic disease and self-limiting back pain 
following drug infusion). One patient was withdrawn from the study due to a drug-related toxicity 
(hyperbilirubinaemia on background of ultrasound suggestive of acute cholecystitis). One patient was 
withdrawn outside the 28-day primary end point window. This was a 52-year-old with HCC, previously 
treated with surgery and sorafenib, who was found to have an elevated GGT following 2 units of 
alcohol consumption and was withdrawn on day 8 of the third cycle. 
 
Pharmacokinetics  
Mean plasma CEBPA-51 concentration vs time profiles for each Q1wk cohort are shown in Figure 1A. 
Overall, there was an increase in exposure with increasing dose and the plasma CEBPA-51 
concentration vs time profiles were similar for the first and the second dose – indicating little drug 
accumulation over this time period.  Although the mean plasma terminal half-life of CEBPA-51 was 
reasonably consistent across the dose cohorts after once-weekly treatment with MTL-CEBPA, total 
plasma clearance and the apparent volume of distribution decrease with increasing dose 
(Supplementary Table 1). The net effect is a supra-proportional increase in exposure across the dose 
range 28-160 mg/m2 (Figure 1B). 
As observed with the Q1wk regimen, when MTL-CEBPA is dosed either twice- or three-times weekly, 
the initial rapid decrease in plasma CEBPA-51 concentration after the end of the infusion is the 
dominant decay phase for the first 6h after dosing. Thereafter, the decay is much slower, although PK 
parameters and an accurate terminal half-life cannot be estimated over these shorter dosing intervals 
(Figure 1C). Plasma CEBPA concentration at 24h after each dose is consistent across all the dosing 
regimens, showing little accumulation of CEBPA-51 even when dosed once-daily (D1, D2, D3) at 70 
mg/m2. 
Within the overall study there was no effect of age (range 27-80 yrs), gender (9F/29M) and 
concomitant medication on the pharmacokinetics of MTL-CEBPA (data not shown). 
The analysis of complement and cytokine assays as stipulated by MHRA as biomarkers for 
oligonucleotide safety was performed on a subset of 24 patients. The vast majority of results were 
within normal ranges or below detection limit. No drug related toxicity emerged from the study of 
these safety parameters (data not shown). 
 





CEBPA mRNA levels were measured from WBCs of patients treated with MTL-CEBPA 24 hours after 
treatment (post treatment) by quantitative real time PCR and presented as relative expression to 
baseline at Day 2, 8 and 15 following treatment (see Supplementary Figure 2). CEBPA mRNA levels 
increased by 1.5-fold consistently across all cohorts treated. When grouped at each time point, CEBPA 
expression levels showed a significant 1.68-fold increase at Day 2; a 1.4 fold increase at Day 8 and 15. 
Changes in WCC and neutrophils following drug administration are demonstrated in Figure 2. There 
were incremental decreases in expression of WBC adenosine, PD-1 and CXCR4 mRNA following drug 
administration to day 15 (see Supplementary Figure 3).  
 
 
Please insert Figures 2 here 
 
Efficacy Analysis  
Twenty-nine patients who received at least two cycles of treatment were evaluable for response 
according to RECIST (Supplementary Table 2). The median follow-up was 2 months (range 0.5-36 
months). In the 28mg/m2 QW cohort a 78-year-old female with HCC and cirrhosis on a background of 
hepatitis B (treated), Child Pugh A5, previously treated with RFA, TACE, surgery, sorafenib, 
enzalutamide/ placebo in a randomised clinical trial (RCT) and an experimental anti-FGFR4 antibody 
achieved a confirmed partial response associated with rapid and dramatic decrease of AFP level. This 
partial response was maintained up to 24 months on treatment and her AFP levels remain within 
normal range (see Supplementary Figure 4). No objective responses were observed at the 47, 70, 98, 
130 and 160 mg/m2 QW, 70 mg/m2 BIW or 70 mg/m2 TIW DLs.  In addition, 12 patients at different 
dose levels achieved stable disease as the best RECIST response at 2 months with 4 maintaining stable 
disease at 6 months.  
 
The mean progression-free survival for the entire patient cohort was 4.6 months (95% CI 2.2-6.9, SE 
1.21) and 4.9 months (95% CI 2.3-7.5, SE1.33) when excluding the patients who did not have HCC as 
primary pathology.  
 
Follow-up  
After discontinuation of MTL-CEBPA 7 patients were treated with TKI as illustrated in Table 3. Of these, 
one patient who was previously treated with ablative therapy, TACE and anti-CTLA4 with anti-PDL1 
was challenged with lenvatinib after MTL-CEBPA therapy and had a partial response but progressed 
at six months post treatment and passed away 9 months following treatment. Three TKI naïve-patients 
were found to have a complete radiological response to TKIs following treatment with MTL-CEBPA. 
One was a 61-year-old male with hepatitis B-related cirrhosis and HCC who was previously treated 
with ablative therapy, TACE and doxorubicin who had complete radiological resolution of his liver 
lesions following treatment with sorafenib which is sustained at 9 months. A second patient was a 67-
year-old male with HCC related to hepatitis C, previously treated with TACE and anti-PDL1 who had 
metastatic lesions in the lungs. Following progression on MTL-CEBPA and subsequent treatment with 
sorafenib experienced a complete radiological response in both liver and lungs 4 months after 
treatment was started. This response is sustained at 12 months follow-up and the longitudinal cross-
sectional imaging is illustrated in Figure 3. The third patient is a 61-year-old male with hepatitis B and 
C previously treated with ablative therapy, TACE and doxorubicin who progressed after 2 cycles of 
MTL-CEBPA (during which time he developed lung metastases) was treated with sorafenib. He has 
shown a complete radiological response to both lung and liver lesions one month after TKI treatment 
which is sustained on follow-up for 7 months. CT images of the lung lesions are shown in 
Supplementary Figure 5. Of the remaining patients, one who had previously been treated with 
lenvatinib had disease progression 2 months after treatment with sorafenib and two patients (one 
treated with sorafenib prior to MTL-CEBPA) treated with regorafenib have stable disease at 3 months 
follow-up, however regorafenib was then discontinued due to toxicity.  
 






This first-in-human and first-in-class multicentre phase I dose and dose escalation study of the RNA 
oligonucleotide MTL-CEBPA has shown the drug to be well tolerated with no maximum tolerated dose 
reached. Based on a combination of safety, pharmacokinetics and pharmacodynamics the 
recommended dose of MTL-CEPBA for further evaluation is 130mg/m2 QW. The toxicity profile was 
favourable and comparable to the other drugs used in this patient population including sorafenib3, 
regorafenib5 and nivolumab16. The non-linear PK behaviour of MTL-CEBPA is suggestive of a saturable 
capacity-limited tissue/cellular uptake process, dominant in the first 6h after dosing over this dose 
range, and a slower linear first-order process thereafter. The pharmacodynamic analysis 
demonstrated target engagement and a reversible and consistent increase of neutrophil count in 
peripheral blood following drug administration.   
 
Although this trial was not powered to evaluate efficacy, there was evidence of anti-tumour activity 
with a mean progression-free survival of 4.6 months in pre-treated patients, despite a relatively 
modest ORR of 4% as monotherapy. The patient who sustained a partial response for 24 months and 
remains on treatment has been found to have a KRAS mutation in the tumour. KRAS mutations are 
known to be associated with a protumour inflammatory microenvironment through activation of 
NFκB and IL2217 as well as IL618 signalling, which may explain this response given the known role of 
CEBPA in immune function. 
 
The clinical activity that we have observed in patients who have progressed on MTL-CEBPA and were 
subsequently challenged with TKI has been unusual. A recent literature review has documented 15 
published cases of complete response to sorafenib in advanced HCC since the drug was introduced in 
2007, including 5 patients with lung metastases19. In the original trial that lead to the approval of 
sorafenib, out of 299 patients randomised to the drug there were no complete responses and only 2 
partial responses3. A further report has suggested that complete responders may have a specific 
immune/inflammatory profile with an associated early dermatologic reaction seen in some of this 
patient group20.  Of the seven cases in this trial that were treated with MTL-CEBPA and then TKIs we 
have observed three complete radiological responses and one partial response; two of the patients 
with a complete response showing complete resolution of multiple lung metastases. The response has 
been fast following drug administration and durable with no subsequent treatment with MTL-CEBPA 
for any of the patients who responded. This signal is therefore unlikely to be attributed to the activity 
of the TKI on its own. Additionally, the significant interval between MTL-CEBPA and TKI treatment 
suggests potential immune modulatory effects of MTL-CEBPA. 
 
There is evidence that modifying the phenotype of specific sub-populations of WBC results in a tumour 
microenvironment which is less immune evasive and may be more responsive to conventional 
therapies. Myeloid-derived suppressor cells are associated with poor response to therapy in multiple 
solid tumours, including liver cancer with radiotherapy and sorafenib. Patel and colleagues described 
the dynamic changes that neutrophils undergo in cancer and demonstrated the mechanism of 
neutrophils' contribution to early tumour dissemination21 highlighting the importance and plasticity 
of these cells in cancer progression.  
 
In an HCC pre-clinical mouse model, Zhou and colleagues have shown that 
TANs recruit macrophages and Treg cells to HCCs to promote their growth, progression, 
and resistance to sorafenib22. Chang et al23 observed that tumour-infiltrating Ly6G+ MDSCs and other 
immune suppressors were increased in orthotopic liver tumours using a syngeneic mouse liver cancer 
cell line. They found that tumour-infiltrating Ly6G+ MDSCs of sorafenib-treated tumours significantly 
induced IL-10 and TGF-β expressing CD4+ T cells, and downregulated the cytotoxic activity of 
CD8+ T cells. The combination of anti-Ly6G antibody or anti-IL-6 antibody with sorafenib significantly 
reduced the cell proportion of Ly6G+ MDSCs in orthotopic liver tumours, enhanced T cell proliferation 
and improved the therapeutic effect of sorafenib. They concluded that modulating the tumour 
microenvironment through targeting tumour-infiltrating Ly6G+ MDSCs represents a strategy to 
improve the oncological efficacy of sorafenib23. 
 
The C/EBP-a transcription factor is known to regulate multiple cellular pathways relevant to HCC. 
Deregulation of C/EBP-a expression has been reported in a variety of human cancers and in HCC, 
C/EBP-a is reported to inhibit cell proliferation, cell motility and metastasis. This is supported by the 
observations that CEBPA knock-in mice have reduced susceptibility to HCC and CEBPA up-regulation 
by saRNA inhibits tumour growth in multiple tumour models9,11,15. It is well described that C/EBP-a 
regulates haematopoiesis by inducing myeloid differentiation. It has been observed that myeloid 
lineage specific deletion of C/EBP-a results in significantly enhanced myeloid-derived suppressor cell 
(MDSC) proliferation and expansion, as well as an increase of myeloid progenitors and a decrease of 
mature cells. Deletion of C/EBP-a in MDSCs enhanced the pro-angiogenic, immune suppressive and 
pro-tumorigenic behaviour of these cells by upregulating the production of iNOS and arginase, as well 
as MMP-9 and VEGF10. In this study we found a consistent and reversible increase in WCC and 
neutrophils in keeping with the hypothesis that PBMC upregulation of CEBPA is associated with 
emergency granulopoiesis and significant increases in the populations of immature monocytes24. We 
also observed downregulation of CXCR4 mRNA in white blood cells following injection of MTL-CEBPA. 
Chen and colleagues have observed in an orthotopic HCC mouse model that CXCR4 inhibition prevents 
polarization towards immunosuppressive HCC microenvironment during Sorafenib treatment and 
that it is also associated with anti-vascular and anti-metastatic effects and HCC progression delay25. 
 
We hypothesise that pre-treatment of the HCC tumour microenvironment with MTL-CEBPA renders it 
more susceptible to the effect of TKIs and based on the proposed mechanism and pre-clinical studies 
(unpublished data) we believe may have synergism with immune checkpoint blockade. This is aligned 
with current developments, as following the reporting of IMBrave 150 the focus on innovation in 
systemic HCC treatment is clearly through combination treatment. The clinical activity of MTL-CEBPA 
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Figure 1: A) Mean ±SEM plasma CEBPA-51 – Q1wk regimen by dose cohort. Plasma CEBPA-51 
concentration vs time profiles were collected over 7 days after the first dose and over 3 days after 
the second dose. Mean data is shown here for each cohort. MTL-CEBPA doses: 28 mg/m2 n=5, 47 
mg/m2 n=4, 70 mg/m2 n=6, 98 mg/m2 n=3, 130 mg/m2 n=3 and 160 mg/m2 n=3. B) Individual 
patient data for B1) dose-normalised plasma CEBPA Cmax (ug/mL / mg/m2) vs dose and B2) dose 
normalised plasma CEBPA AUC infinity (ug.h/mL / mg/m2) vs dose after the first dose for patients 
treated with the Q1wk dosing regimen. (Non-HCC – red squares; HCC Viral / HCC-fibrolamellar – 
orange circles; HCC Non-viral (ALD and cirrhosis) - green squares; (NAFLD) green circle; HCC 
Unknown aetiology – blank circles). C) Plasma CEBPA concentration data was collected over 7 days 
after dosing 70 mg/m2 MTL-CEBPA twice-weekly, C1) at 0 and 24h (D1, D2, n=6); C2) at 0 and 72 (D1, 
D3, n=5); and three times weekly C3) at 0, 24 and 72h (D1, D2, D3, n=3). Each patient is represented 
by a different symbol. There was little accumulation of CEBPA after either two or three consecutive 
daily doses. 
 
Figure 2 Mean changes in A) Neutrophils and B) White Cell Count following administration of MTL-
CEBPA on day 1 (n=5 at 70 mg/m2) 
 
Figure 3 illustrating radiological response in liver and lungs. Red arrow – indicating peritoneal 
metastasis / hepatic extension (which was irradiated on 14/7/18 due to intrahepatic bleed and severe 
pain). Yellow arrow – HCC. Green arrows – Lung mets which were no longer present on 5/3/18 (2 
months after was started sorafenib) and 3/7/18 (2 months after sorafenib was stopped) 
 
Supplementary Figure 1 Dose escalation flow chart. DLT – dose limiting toxicity, MTD – maximum 
tolerated dose 
 
Supplementary Figure 2 qPCR of CEBPA mRNA levels at days 2, 8 and 15 following treatment 
 
Supplementary Figure 3 Longitudinal changes in WBC mRNA expression of CEBPA, adenosine, PD-1 & 
CXCR4 at screening, day2, 8 and 15 of a single patient treated in the 130mg/m2 cohort 
 
Supplementary Figure 4 A) CT and MRI of patient with prolonged partial response with MTL-CEBPA 
treatment B) IFN-gamma, NFkB and IL6 trend at days 1, 8 and 15 following treatment and C) AFP 
change at from baseline to 4, 8 and 16 weeks on treatment 
 





















































  n=5 n=4 n=6 n=3 n=3 n=3 n=5 n=6 n=3 N=38 
















69) 63 (54-77) 
68 (52-
77) 66 (27-80) 
Gender                     
Female 3  1  1  2  - - - 2  - 9  
Male 2  3  5  1  3  3  5  4  3 29  
 
ECOG-PS                     
0 2  2  3  1  2  1  2  2  1  16  
1 3  2  3  2  1  2  3  4  2  22 
Tumour type, n 
(%)                     
HCC  2  1  5  3  3  3  5  6  3  31  
Fibrolamellar 
HCC - 2  - - - - - - - 2  
CRC 3  - 1  - - - - - - 4  
Ampulary - 1  - - - - - - - 1  
Child-Pugh                     
A5 1  2  3  3  3  1  3  4  2  22  
A6 - - 1 - - 1  1  1  1  5  
B7 1  1  1  - - 1  1  1  - 6  
B8                     
Extrahepatic 
metastasis                      
Yes 4  3  4  3  2  1  2  3  1  23  
No 1  1  2  - 1  2  3  3  2  15  
Cause of HCC                     
Hepatitis B 2  - 3  - 2  1  - 2  - 10  
Alcoholic 
disease - 1  2  - - - 2  - 1  6 
Hepatitis C - - - 1  - 1  1  1  - 4  
NAFLD/ NASH - - - 2  - 1 2 1  1 7 
Haemochromat
osis - - - - - - - 1  1  2  
































Prior therapy                     
Surgery 4  3  2  1  1  2  1  1  1  16  
                     
Transarterial 
chemobolisation  2  - 3  3  2  2  1  4  1  18  
RFA 1  1  - - - 1  - 1  - 4  
IRE 1  - - - - - - - - 1  
Other 1  - - - 1  - 1  1  - 4  
Radiation 2 2 - 1 - 2 - 1 1 9  
None - 1  1  - 1  - 4  2  - 9  
Prior systemic 
therpay                     
TKI 1  1  5  1  1  2  5  5  3  24  
ICB - - 2  3  2  2  - - - 9  
FGFRi 1  - - 2  - - - - - 3  
Other 
chemotherapy 4  3  1  - 1  - - 1  - 10  
None - - - - - - - - - - 

Table 2 Most frequently (>5%) reported drug related adverse AE in each cohort presented as n (%) 
 
n=5 n=4 n=6 n=3 n=3 n=3 n=5 n=6 n=3 N=38
Frequent AEs Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3 Any grade Gr. 3
Fatigue 2 (40.0) - - - 4 (66.7) 1 (16.7) 1 (33.3) - - - - - 1 (20.0) - 1 (16.7) - - - 9 (23.7) 1 (2.6)
Thrombocytopenia 1 (20.0) 1 (20.0) - - - - 1 (33.3) - - - - - 1 (20.0) - 1 (16.7) - 1 (33.3) 1 (33.3) 5 (13.2) 2 (5.3)
Anaemia 2 (40.0) 1 (20.0) - - 1 (16.7) - 1 (33.3) 1 (33.3) - - - - 1 (20.0) - - - - - 5 (13.2) 2 (5.3)
AST increased - - - - 2 (33.3) - 2 (66.7) 1 (33.3) - - - - 1 (20.0) - - - - - 5 (13.2) 1 (2.6)
Blood ALP increased 1 (20.0) - 1 (25.0) - 1 (16.7) - - - - - - - 1 (20.0) - - - - - 4 (10.5) -
Hypoalbuminaemia 1 (20.0) - 1 (25.0) - - - - - - - - - 1 (20.0) - 1 (16.7) - - - 4 (10.5) -
ALT increased - - - - 1 (16.7) - 1 (33.3) - 1 (33.3) 1 (33.3) - - 1 (20.0) - - - - - 4 (10.5) 1 (2.6)
Blood bilirubin increased - - - - 2 (33.3) - 1 (33.3) - - - - - - - - - 1 (33.3) - 4 (10.5) -
Pyrexia 1 (20.0) - 1 (25.0) - 1 (16.7) - - - - - - - - - - - - - 3 (7.9) -
Hypophosphataemia 2 (40.0) 1 (20.0) - - - - 1 (33.3) 1 (33.3) - - - - - - - - - - 3 (7.9) 2 (5.3)
Neutrophil count increased 1 (20.0) - 1 (25.0) - 1 (16.7) - - - - - - - - - - - - - 3 (7.9) -
Diarrhoea - - 2 (50.0) - 1 (16.7) - - - - - - - - - - - - - 3 (7.9) -
Flushing 1 (20.0) - - - 1 (16.7) - - - - - - - - - - - - - 2 (5.3) -
Ascites - - - - 1 (16.7) - - - - - - - - - 1 (16.7) - - - 2 (5.3) -
GGT increased - - - - - - 1 (33.3) 1 (33.3) - - - - 1 (20.0) 1 (20.0) - - - - 2 (5.3) 2 (5.3)
Dysgeusia - - - - 1 (16.7) - - - - - - - - - 1 (16.7) - - - 2 (5.3) -
Dizziness - - - - 1 (16.7) - - - - - - - - - 1 (16.7) - - - 2 (5.3) -











































Table 3 Characteristics and responses of patients receiving TKI after MTL-CEBPA. Patients below 








































No 8 No 































ar lymph node 
No 2 No 
































No No 2 No 















Lung No 8 Yes 














No 2 Yes 
PD - after 2 
months 
Sorafenib  
      
ICB = immune-checkpoint blockade; SIRT = selective internal radiation therapy; TKI = tyrosine kinase 





















28 5 1.00 1.68 ± 0.98 30.7 ± 30.6 2.08 ± 2.18 98.7 ± 103.0 49.2 ± 20.4 
47 4 1.00 6.33 ± 1.87 98.7 ± 106.1 0.91 ± 0.61 37.1 ± 17.6 45.2 ± 20.6 
70 6 1.00 15.50 ± 1.51 219.5 ± 82.4 0.37 ± 0.18 21.3 ± 4.1 49.1 ± 20.2 
98 3 1.25 20.14 ± 7.62 408.2 ± 113.8 0.26 ± 0.85 21.6 ± 7.9 59.2 ± 18.5 
130 3 1.25 39.43 ± 14.24 499.1 ± 186.2 0.29 ± 0.12 20.6 ± 7.9 50.7 ± 12.0 
160 3 1.00 67.45 ± 10.92 836.3 ± 51.2 0.19 ± 0.01 8.5 ± 0.7 30.8 ± 4.1 
Mean non-compartmental PK parameters ± SD: Tmax – time of maximum observed concentration (median); 
Cmax – maximum observed concentration; AUCinf – area under the curve calculated from 0-last observed 
concentration and extrapolated to infinity; CL – total plasma clearance (Dose/AUCinf); Vz – apparent volume of 
distribution based on the terminal phase; half-life – terminal half-life calculated using at least three data points 




Supplementary Table 2 RECIST 1.1 response observed overall and per cohorts in HCC patients at cut-
off (12 Sep 2018) presented as n (%) 
 
Cohort N PR SD 6m SD >2m SD 2m PD NE 
28 mg/m2 QW 2 1 (50.0) - - - 1 (50.0) - 
47 mg/m2 QW 3 - - - - 2 (66.7) 1 (33.3) 
70 mg/m2 QW 5 - 1 (20.0) - 2 (40.0) 2 (40.0) - 
98 mg/m2 QW 3 - 2 (66.7) - - 1 (33.3) - 
130 mg/m2 QW 3 - 1 (33.3) - - 2 (66.7) - 
160 mg/m2 QW 3 - - 1 (33.3) 2 (66.7) - - 
70mg/m2 BIW D1&3 5 - - - 1 (20.0) 2 (40.0) 2 (40.0) 
70mg/m2 BIW D1&2 6 - - - 2 (33.3) 4 (66.7) - 
70mg/m2 TIW 3 - - - - 1 (33.3) 2 (66.7) 
Overall 33 1 (3.0) 4 (12.1) 1 (3.0) 7 (21.2) 15 (45.5) 5 (15.2) 
        
